SCHEMBL4622121

SCHEMBL4622121

C=CCc1cccc(CC(NC(=O)OC(C)(C)C)C2CC(C)C(=O)O2)c1

nearest known ligand 0.37

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CTSS P25774 5/20 0.37
CTSK P43235 4/20 0.37
CTSB P07858 3/20 0.37
CTSL P07711 2/20 0.36
ATM Q13315 1/20 0.35
ACE P12821 1/20 0.35
KLK5 Q9Y337 1/20 0.35
ALDH1A1 P00352 1/20 0.35
CYP3A4 P08684 1/20 0.35
CYP2D6 P10635 1/20 0.35
CYP2C9 P11712 1/20 0.35
CYP2C19 P33261 1/20 0.35
MAPT P10636 1/20 0.34
SLC7A5 Q01650 1/20 0.34
PPARG P37231 1/20 0.34
PPARA Q07869 1/20 0.34
EPHX2 P34913 1/20 0.34
SCN9A Q15858 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4622124 1.00 CTSS (0.37) CTSSCTSKCTSBCTSLATM
SCHEMBL4906884 0.87 CTSS (0.33) CTSSCTSKCTSBCTSLCYP2C19
SCHEMBL4881213 0.87 CTSS (0.39) CTSSCTSKCTSBCTSLATM
SCHEMBL4881219 0.87 CTSS (0.39) CTSSCTSKCTSBCTSLATM
SCHEMBL2532411 0.86 CTSS (0.40) CTSSCTSKCTSBCTSLATM
SCHEMBL2532413 0.86 CTSS (0.40) CTSSCTSKCTSBCTSLATM
SCHEMBL4042106 0.85 ATM (0.48) CTSSCTSKCTSBCTSLATM
SCHEMBL5620023 0.85 ATM (0.48) CTSSCTSKCTSBCTSLATM
SCHEMBL4042099 0.85 ATM (0.48) CTSSCTSKCTSBCTSLATM
SCHEMBL5620017 0.85 ATM (0.48) CTSSCTSKCTSBCTSLATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080132477-A1 Macrocyclic Compounds Useful as Bace Inhibitors NOVARTIS AG (CH) 2008-06-05 US disclosed
US-20080070885-A1 MACROCYCLIC COMPOUNDS HAVING ASPARTIC PROTEASE INHIBITING ACTIVITY AND PHARMACEUTICAL USES THEREOF NOVARTIS AG (CH) 2008-03-20 US disclosed
EP-1654241-B1 MACROCYCLIC COMPOUNDS HAVING ASPARTIC PROTEASE INHIBITING ACTIVITY AND PHARMACEUTICAL USES THEREOF NOVARTIS AG (CH) 2008-03-19 EP disclosed
US-20060223745-A1 Macrocyclic compounds having aspartic protease inhibiting activity and pharmaceutical uses thereof BETSCHART CLAUDIA 2006-10-05 US disclosed
EP-1654241-A1 MACROCYCLIC COMPOUNDS HAVING ASPARTIC PROTEASE INHIBITING ACTIVITY AND PHARMACEUTICAL USES THEREOF Novartis AG (CH) 2006-05-10 EP disclosed
WO-2005003106-A1 MACROCYCLIC COMPOUNDS HAVING ASPARTIC PROTEASE INHIBITING ACTIVITY AND PHARMACEUTICAL USES THEREOF NOVARTIS AG (CH) 2005-01-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060223745-A1 Macrocyclic compounds having aspartic protease inhibiting activity and pharmaceutical uses thereof BACE1, APP, ACE CTSS 45/4885CTSK 121/4885CTSB 93/4885
US-20080132477-A1 Macrocyclic Compounds Useful as Bace Inhibitors BACE1, BACE2, APP CTSS 11/4885CTSK 60/4885CTSB 18/4885
US-20080070885-A1 MACROCYCLIC COMPOUNDS HAVING ASPARTIC PROTEASE INHIBITING ACTIVITY AND PHARMACEUTICAL USES THEREOF BACE1, APP, BACE2 CTSS 48/4885CTSK 114/4885CTSB 79/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.